SCHEMBL28069946

SCHEMBL28069946

COC(=O)c1cccc(OCC(F)(F)F)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MRGPRX4 Q96LA9 4/20 0.56
CYSLTR1 Q9Y271 1/20 0.51
SMN1; SMN2 Q16637 3/20 0.50
NPC1 O15118 2/20 0.50
RAB9A P51151 2/20 0.50
POLB P06746 1/20 0.50
BLM P54132 1/20 0.50
MAOB P27338 2/20 0.49
CYP1A2 P05177 1/20 0.49
CYP2C9 P11712 1/20 0.49
TP53 P04637 1/20 0.49
LOXL2 Q9Y4K0 1/20 0.49
MAPT P10636 2/20 0.48
HTT P42858 1/20 0.48
ALDH1A1 P00352 1/20 0.48
CYP4F2 P78329 1/20 0.48
CYP4A11 Q02928 1/20 0.48
NR1H2 P55055 1/20 0.47
GAA P10253 1/20 0.47
XBP1 P17861 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5752927 0.86 MRGPRX4 (0.53) MRGPRX4CYSLTR1SMN1; SMN2NPC1RAB9A
SCHEMBL2714234 0.84 MAOB (0.66) SMN1; SMN2MAOBMAPTHTT
SCHEMBL10068542 0.84 NOTUM (0.49) MRGPRX4SMN1; SMN2NPC1RAB9APOLB
SCHEMBL30281213 0.83 NR4A2 (0.63) MRGPRX4NPC1RAB9AL3MBTL1
SCHEMBL2946154 0.83 NR4A2 (0.63) MRGPRX4NPC1RAB9AL3MBTL1
SCHEMBL27439509 0.83 MRGPRX4 (0.59) MRGPRX4CYSLTR1SMN1; SMN2NPC1RAB9A
SCHEMBL5153039 0.82 MRGPRX4 (0.50) MRGPRX4CYSLTR1SMN1; SMN2NPC1RAB9A
SCHEMBL27931854 0.82 MAOB (0.49) MRGPRX4SMN1; SMN2NPC1RAB9AMAOB
SCHEMBL15036779 0.81 PARP1 (0.56) MRGPRX4SMN1; SMN2MAOBCYP1A2CYP2C9
SCHEMBL16957782 0.81 MAOB (0.50) MRGPRX4MAOBCYP1A2CYP2C9MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105555766-A Aminomethyl-biaryl derivatives as complement factor D inhibitors and uses thereof NOVARTIS AG 2016-05-04 CN disclosed